Table 2.

Clinical features and type of CD19-directed immunotherapy received by the 53 patients with R/R B-ALL and used for clinicobiological correlations

Groupn
Adult vs Pediatric  
 Pediatric* 15 
 Adult 38 
CD19-directed immunotherapy  
 Blinatumomab 16 
 Kymriah 14 
 ARI001† 23 
Clinical outcome  
 Relapse 27 
 No relapse 26 
Groupn
Adult vs Pediatric  
 Pediatric* 15 
 Adult 38 
CD19-directed immunotherapy  
 Blinatumomab 16 
 Kymriah 14 
 ARI001† 23 
Clinical outcome  
 Relapse 27 
 No relapse 26 

Adapted from Ortiz-Maldonado et al.22,23

*

Age < 18 years.

†

Academic local CD19 CAR phase 1/2 trial (completed).

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal